SAB Biotherapeutics Inc
SABS
Market Cap$33.49M
Close$
$6.76
86.3% upside
Current Fair Value
86.3% upsideUndervalued by 86.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $33.49 Million |
|---|---|
| Enterprise Value | $-17,170,464.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-7.64 |
| Beta | 0.12 |
| Outstanding Shares | 9,225,494 |
| Avg 30 Day Volume | 6,057 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.79 |
|---|---|
| PEG | -0.42 |
| Price to Sales | - |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | -7.67 |
| Enterprise Value to EBIT | 0.45 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.34 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
ESG Score
No data
About SAB Biotherapeutics Inc
81 employeessab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.